Medtronic’s Portfolio Overhaul and Product Push Leave Investors Cold
19.06.2026 - 18:24:25 | boerse-global.de
Medtronic has been reshaping its business on multiple fronts this year, spinning off its diabetes division, closing a $550 million acquisition in neurovascular care, and launching a new heart ablation system in India. Yet the stock remains stuck in a steep slide, down nearly 16% since January, as investors weigh the costs of transformation against the promise of future growth.
The acquisition of Scientia Vascular, a Salt Lake City-based developer of specialty catheters and guidewires, closed in mid-June and has been folded into Medtronic’s neurovascular unit. The deal, which could include additional performance-based payments, is designed to improve mechanical thrombectomies and other stroke interventions. Medtronic expects the purchase to start contributing meaningfully to earnings after fiscal 2027.
Alongside the acquisition, Medtronic’s annual report revealed a $150 million tax provision tied to the transfer of intellectual property between subsidiaries, plus $66 million in costs from the amortization of tax assets — a reminder of the complexities embedded in the company’s global structure. For shareholders, the next milestone is the June 26 ex-dividend date, when the stock will trade without the $0.72 quarterly payout. At current levels, that equates to a yield of roughly 3.6%.
Should investors sell immediately? Or is it worth buying Medtronic?
The company has also streamlined its corporate focus. Management has narrowed operations to three core segments: cardiovascular, neuroscience, and medical surgery, with an emphasis on artificial intelligence and robotics. The diabetes unit has been spun off entirely. Medtronic now employs more than 95,000 people globally and, according to its latest filing, faces no new significant legal challenges or restructuring costs. On Thursday, the company launched its PulseSelect ablation system in India, betting on the fast-growing Asian healthcare market, while also expanding distribution of cardiac monitors in Europe.
The market, however, has yet to reward the strategic shift. The stock closed Thursday near €69, and at €68.92 is wrestling with its 50-day moving average at €68.53. Analysts remain split: Barclays rates the shares a buy with a $120 target, while Truist rates them a hold at $86, calling for stronger earnings growth before a more bullish stance. The consensus price target stands at roughly $99.
The broader medical technology market is expanding rapidly, with research firms projecting the segment for ECG patches and thrombosis devices could reach $9 billion by 2036. Medtronic’s recent moves — from the diabetes spin-off to the Scientia acquisition and the India launch — are intended to position it for that wave. But with the stock deep in the red, the pressure is on: the new assets will need to start delivering tangible profit growth by fiscal 2027 for the transformation story to gain traction.
Ad
Medtronic Stock: New Analysis - 19 June
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
